AU2021324665A1 - Methods of treating gout - Google Patents

Methods of treating gout Download PDF

Info

Publication number
AU2021324665A1
AU2021324665A1 AU2021324665A AU2021324665A AU2021324665A1 AU 2021324665 A1 AU2021324665 A1 AU 2021324665A1 AU 2021324665 A AU2021324665 A AU 2021324665A AU 2021324665 A AU2021324665 A AU 2021324665A AU 2021324665 A1 AU2021324665 A1 AU 2021324665A1
Authority
AU
Australia
Prior art keywords
mtx
infusion
sua
week
pegloticase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021324665A
Other languages
English (en)
Inventor
Brian LAMOREAUX
Paul PELOSO
Swarnendra VERMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics USA Inc
Original Assignee
Horizon Therapeutics USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics USA Inc filed Critical Horizon Therapeutics USA Inc
Publication of AU2021324665A1 publication Critical patent/AU2021324665A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y107/00Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Glass Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021324665A 2020-08-10 2021-08-10 Methods of treating gout Pending AU2021324665A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063826P 2020-08-10 2020-08-10
US63/063,826 2020-08-10
US202163148982P 2021-02-12 2021-02-12
US63/148,982 2021-02-12
PCT/US2021/045350 WO2022035828A1 (en) 2020-08-10 2021-08-10 Methods of treating gout

Publications (1)

Publication Number Publication Date
AU2021324665A1 true AU2021324665A1 (en) 2023-04-13

Family

ID=80247297

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021324665A Pending AU2021324665A1 (en) 2020-08-10 2021-08-10 Methods of treating gout

Country Status (11)

Country Link
US (2) US20230301999A1 (https=)
EP (2) EP4588513A3 (https=)
JP (1) JP2023537403A (https=)
KR (1) KR20230086660A (https=)
CN (1) CN116261463A (https=)
AU (1) AU2021324665A1 (https=)
BR (1) BR112023002458A2 (https=)
CA (1) CA3189100A1 (https=)
IL (1) IL300536A (https=)
MX (1) MX2023001740A (https=)
WO (1) WO2022035828A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP4588513A3 (en) * 2020-08-10 2025-10-22 Horizon Therapeutics USA, Inc. Methods of treating gout
WO2024088213A1 (en) * 2022-10-24 2024-05-02 Westlake Therapeutics (Shanghai) Co., Limited Combination to induce specific immune tolerance
US12201413B2 (en) 2023-03-01 2025-01-21 Washington University Free breathing dynamic contrast enhanced (DCE) liver MR imaging
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000008196A2 (en) * 1998-08-06 2000-02-17 Duke University Urate oxidase
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
SG161247A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク. 陽イオン界面活性剤によるタンパク質の精製
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
KR20180120753A (ko) * 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
ES3036482T3 (en) * 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2020160325A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160324A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP4588513A3 (en) * 2020-08-10 2025-10-22 Horizon Therapeutics USA, Inc. Methods of treating gout

Also Published As

Publication number Publication date
MX2023001740A (es) 2023-04-05
CA3189100A1 (en) 2022-02-17
EP4588513A2 (en) 2025-07-23
BR112023002458A2 (pt) 2023-05-02
CN116261463A (zh) 2023-06-13
WO2022035828A1 (en) 2022-02-17
IL300536A (en) 2023-04-01
KR20230086660A (ko) 2023-06-15
JP2023537403A (ja) 2023-08-31
US20220323445A1 (en) 2022-10-13
EP4588513A3 (en) 2025-10-22
EP4192581A1 (en) 2023-06-14
US20230301999A1 (en) 2023-09-28
EP4192581A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
EP4192581A1 (en) Methods of treating gout
US20240033331A1 (en) Reducing immunogenicity to pegloticase
US12465631B2 (en) Reducing immunogenicity to pegloticase
US20250009849A1 (en) Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US20220323550A1 (en) Pegloticase for treatment of gout in renal transplant recipients
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US12194030B2 (en) Treatment of migraine
US20220409620A1 (en) Reducing immunogenicity to pegloticase
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
RU2860237C2 (ru) Способы лечения подагры
HK40128278A (en) Methods of treating gout
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury
US20260124185A1 (en) Treatment of migraine
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
JP2026513190A (ja) シェーグレン症候群の治療及び予防のためのCD40L特異的Tn3由来足場
AU2024210360A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy